MedTrace Logo

ctDNA-MRD in Stage IIIB-C NSCLC Patients Treated With Induction Chemoimmunotherapy

NCT05822284 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2023-04-20

No results posted yet for this study

Summary

The goal of this observational study is to explore whether ctDNA-MRD dynamic monitoring can more effectively predict the therapeutic effect of induction chemoimmunotherapy followed by surgery or non-surgical treatment for stage IIIB-C driver-negative NSCLC in the MDT model, so as to accurately guide clinical diagnosis and treatment.

Conditions

Interventions

DIAGNOSTIC_TEST

NGS and ctDNA-MRD detection

NGS and ctDNA-MRD detection

Sponsors & Collaborators

  • Geneplus-Beijing Co. Ltd.

    collaborator INDUSTRY

  • Second Xiangya Hospital of Central South University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-30
Primary Completion
2029-03-31
Completion
2029-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05822284 on ClinicalTrials.gov